Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!
Jun 18, 2019
Bluebird declares the price of its gene therapy- Zynteglo Bluebird Bio has set the price of its gene therapy Zynteglo at USD 1.8 million. Zynteglo, so far, has only been approved for treating rare blood disorders in the Europe Union. The full price of Zynteglo can be dispersed out for five years, at approx...
Read More...
Jun 07, 2019
In layman’s language, Cluster headache is a headache disorder that occurs in cyclical patterns. The term cluster headache itself defines the condition that these attacks occur in groups, or “clusters.” During a cluster cycle, brief, excruciatingly severe headache attacks recur between 1-8 times per day. Known as on...
Read More...
Jun 04, 2019
Sanofi’s Isatuximab combo extends lives in multiple myeloma Phase III trials of Sanofi’s investigational anti-CD38 monoclonal antibody, isatuximab combination therapy were successful in lowering down the multiple myeloma tumor rate in 60% of the patients in comparison to 35% reduction in the patients taking the...
Read More...
May 30, 2019
Iovance infuses USD 75 M to boost Cancer therapy Iovance Biotherapeutics is all set to build a 136,000-square-foot facility in Philadelphia to develop cancer therapies using its tumour-infiltrating lymphocyte (TIL) technology. Building the new facility will cost the Iovance around USD 75 Million. The biotherapeu...
Read More...
May 27, 2019
The U.S. FDA recently approved the much talked about Novartis’s drug Zolgensma for treating a life-threatening condition Spinal Muscular Atrophy (SMA). SMA is a neuromuscular disorder that worsens the muscles over time. It happens due to a mutation in the SMN1 gene that results in the deficiency of an SMN pro...
Read More...
May 09, 2019
AstraZeneca-Daiichi breast cancer treatment scored promising results The breast cancer drug trastuzumab deruxtecan developed by AstraZeneca and Daiichi Sankyo showed positive results in a metastatic breast cancer trial. AstraZeneca remunerated Daiichi Sankyo USD 1.35 billion upfront and guaranteed up to USD 6.9 ...
Read More...
Apr 26, 2019
Spinal Muscular Atrophy (SMA) is a genetic disorder that affects the part of the nervous system which controls the voluntary movement of limbs and muscles. SMA results in the loss of motor neurons in the Spinal Cord. SMA is one of the most common causes of infant mortality and mobility impairment. Spinal Muscular A...
Read More...
Apr 03, 2019
What exactly is Marijuana? In a layman language, Marijuana is the dried buds and leaves of a plant Cannabis sativa favored in warm, wild tropical climates. Earning names like pot, ganja, weed, hemp, hash, etc. it contains around 104 active cannabinoids (CBD). What they do is, they mimic the signal producing che...
Read More...
Mar 28, 2019
Saama Technologies raises USD 40 Million to bolster AI Saama Technologies has got a hefty investment of USD 40million to accelerate its Artificial Intelligence and bolster its use in the branch of Life Sciences. This will help the California based data analytics company to innovate, curate and accelerate the cli...
Read More...
Feb 28, 2019
Cell Medica receives funds for its cell therapy A USD 8.7 million grant to Cell Medica has been given by Cancer Prevention and Research Institute of Texas (CPRIT) to speed up the clinical development of CMD-502 off-the-shelf chimeric antigen receptor-natural killer T cell (CAR-NKT) cell therapy. The program, su...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
Newsletter/Whitepaper